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Abstract
Background: The transmembrane glycoprotein CD44 is a major hyaluronan cell surface receptor
widely distributed in eye tissues and fluids. The shed ectodomain of CD44 is termed soluble CD44
and is toxic to human retinal ganglion cells in cell culture. The purpose of this study was to
investigate the concentration of sCD44 in the aqueous humor (AH) of normal subjects, patients
with primary open-angle glaucoma, and patients with degenerative myopia but without glaucoma,
to determine if the molecule might serve as a protein marker of glaucoma.
Findings: In this case-control study, AH samples were collected from controls (n = 16), patients
with primary open-angle glaucoma (n = 11), and patients with degenerative myopia (n = 11) who
underwent phacoemulsification surgery to treat mature or immature cataracts. The sCD44
concentration in AH was measured using a commercial ELISA kit.
In normal AH samples the sCD44 concentration was 5.40 ± 1.21 ng/mL, whereas in degenerative
myopia patients the sCD44 concentration was 5.76 ± 1.15 ng/mL. There was thus no statistically
significant difference between these two groups (p > 0.05). The aqueous sCD44 concentration in
patients with primary open-angle glaucoma (12.2 ± 10.1 ng/mL) was higher than that of the control
group (p < 0.05).
Conclusion: sCD44 may be a protein marker of primary open-angle glaucoma.
Background
Glaucoma, a leading cause of visual impairment and
blindness worldwide, is characterized by excavation of the
optic nerve head and selective apoptotic loss of retinal
ganglion cells (RGCs), resulting in a progressive decline in
visual function [1]. There are several types of glaucoma
(includingopen-angle, normal tension, and early-onset).
Primary open-angle glaucoma (POAG) is the most com-
mon form of disease. The major risk factor for most glau-
comas and POAG is increased intraocular pressure [1].
Intraocular pressure is a function of the production of liq-
uid aqueous humor (AH) by the ciliary processes of the
eye and drainage thereof through the trabecular mesh-
work (TM). Myopia, or short-sightedness, is the most
common form of vision disorder worldwide. Higher lev-
els of myopia, usually defined as an axial eye length >26
mm or a refractive error of < -6.00 diopters (D), are often
designated as 'degenerative' myopia. Patients with high
levels of myopia (spherical equivalent at least -6.0 D) are
more susceptible to glaucoma [2].
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The majority of aqueous outflow resistance in both nor-
mal and glaucomatous eyes lies within the TM, especially
within the extracellular matrix of the juxtacanalicular con-
nective tissue, which is a glycosaminoglycan-enriched
area [3]. The transmembrane glycoprotein CD44 is a
major hyaluronic acid (HA) cell-surface receptor widely
distributed in eye tissues and fluids [4]. CD44 functions as
a platform for growth factors and membrane-associated
matrix metalloproteinases (MMPs), thereby entrapping
molecules affecting growth, and bringing enzymes and
substrates together [5]. In addition, CD44 is required for
activation of certain high-affinity receptors (e.g., those
involved in erbB2 phosphorylation and erbB2-erbB3 het-
erodimerization) required for cell survival [6]. Proteolytic
cleavage of the extracellular domain of CD44 by MMPs
releases sCD44, which has biological functions that differ
from those of the intact CD44 protein [7]. It has recently
been shown that sCD44 adversely affects retinal ganglion
cells and TM cell survival in vitro, by activating a proapop-
totic pathway [8].
The purpose of the present study was to investigate the
concentration of sCD44 in the AH of normal subjects, and
patients with POAG and degenerative myopia without
glaucoma, to determine if this molecule might serve as a
protein marker of glaucoma.
Patients and Methods
The patients enrolled in this study were derived exclu-
sively from the Turkish population. Eleven POAG patients
(six male, five female), 11 degenerative myopia patients
(four male, seven female) who underwent phacoemulsifi-
cation surgery to treat mature or immature cataracts, and
16 normal patients (eight male, eight female), were
selected for this case-control study. All subjects underwent
a systematic examination of the optic disc, visual field
examination with automated static white-on-white
threshold perimetry using the 30-2/24-2 program of the
Octopus Visual Field Analyzer (Interzeag, Schlieren, Swit-
zerland), and IOP measurement employing Goldmann
applanation tonometry (Haag Streit, Bern, Switzerland).
AH specimens from anterior chambers were obtained dur-
ing phacoemulsification surgery. Exclusion criteria
included prior incisional ocular surgery, other ophthalmic
diseases (for example, uveitis or progressive retinal dis-
ease), and diabetes mellitus. Patients provided informed
consent after the nature and consequences of the study
were explained, in accordance with the tenets of the Dec-
laration of Helsinki.
An attempt was made gather AH samples under uniform
conditions. Thus, the duration of body rest in the supine
position in the operating theatre, and the temperature of
the theatre, were standardized. A small amount of AH (50
μL) was aspirated using a 27-gauge needle on a tuberculin
syringe, with special care to avoid blood contamination.
Immediately after collection, aqueous samples were
stored at -20°C until analysis. Samples that could not be
evaluated within 4 months of storage were not included in
this study. The aqueous concentration of sCD44 was
measured using a commercial ELISA kit (Bender MedSys-
tems, Wien, Austria).
Statistical analysis
Means and standard deviations were calculated and we
performed nonparametric Mann-Whitney U tests to com-
pare sCD44 concentrations in normal AH, POAG AH, and
degenerative myopia AH samples. A p value < 0.05 was
considered significant.
Results
The clinical data from patients with POAG, and degenera-
tive myopia without glaucoma, compared with those of
normal subjects, are summarized in Table 1. In normal
aqueous samples the sCD44 concentration was 5.40 ±
1.21 ng/mL, and in degenerative myopia patients the con-
centration was 5.76 ± 1.15 ng/mL. There was no statisti-
cally significant difference between these two groups (p >
0.05). The aqueous sCD44 concentration of patients with
POAG (12.2 ± 10.1 ng/mL) was higher than that of the
control group (p < 0.05).
Discussion
AH is an important intraocular fluid responsible for the
supply of nutrients to and removal of metabolic wastes
from the avascular tissues of the eye [9]. AH contains pro-
teins secreted from anterior segment tissues, and these
proteins could play roles in the pathogenesis of various
eye diseases [10]. Several studies have demonstrated that
Table 1: The clinical parameters of age, gender, refractive error, duration of POAG, cup-disc ratio in each of the cohorts (control, 
POAG including duration of POAG, and myopia)
Control POAG Degenerative myopia
Age 65 ± 8 63 ± 10 57 ± 11
Gender 8 M/8 F 6 M/5 F 4 M/7 F
Refractive error +0.9 ± 0.18 +1.1 ± 1.5 -14.3 Dsph ± 7.0
Average Cup/disc ratio 0.47 ± 0.20 0.60 ± 0.26 0.40 ± 0.20
Duration of POAG 11 ± 6BMC Research Notes 2009, 2:224 http://www.biomedcentral.com/1756-0500/2/224
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changing levels of certain AH proteins correlate with the
mechanism or prognosis of many eye disorders [11-13].
In the present study, we directed our attention to AH col-
lected directly from patients. Despite the small number of
participants, we found that the sCD44 level was increased,
with statistical significance, in the AH of POAG patients
compared with normal subjects and degenerative myopia
patients without glaucoma. The sCD44 level was only
slightly elevated in degenerative myopia patients, but this
difference was not statistically significant. It is nonetheless
possible that a study with a larger patient series would
show elevated sCD44 in the AH of such patients. A similar
observation was reported by Knepper and colleagues, who
found a significant increase in AH sCD44 level in POAG
and normal-tension glaucoma patients [14,15].
Only a few studies have explored the functions and clini-
cal importance of aqueous sCD44;both aspects thus
remain poorly understood. According to previous reports,
the bioavailability of sCD44 depends on binding to HA,
and the extent of such binding is influenced by pressure.
HA has hydrophobic patches affected by elevated pres-
sure, as demonstrated by electron microscopy and rotary
shadowing [16]. In normal AH, HA binds to and inacti-
vates sCD44 [17]. In POAG TM and AH, HA concentra-
tion is decreased and AH sCD44 level is twice the normal
value [7,14,18]. Once the concentration of sCD44 attains
a particular threshold, the molecule becomes cytotoxic to
some target cells (e.g., TM cells, RGCs, or supporting cells
in the prelaminar portion of the optic nerve) [17]. Knep-
per and co-workers hypothesized that the apparent
change in the HA polymer with increased pressure, and
the decreased binding of sCD44 to HA under such circum-
stances, may partly explain why increased IOP is a clinical
risk factor for POAG [17].
In the present study, sCD44 concentration in POAG AH
showed wide variation. It is known that POAG is a genet-
ically heterogeneous disorder, featuring interaction of
multiple genes and affected by environmental influences
[19]. We suggest that the increase in sCD44 concentration
in POAG AH is secondary to an underlying heterogeneous
pathophysiology and that AH levels of sCD44 may be
influenced by other factors.
In a previous study, Nolan and associates examined corre-
lations between AH sCD44 concentration and known
POAG risk factors [20]. In the cited work, sCD44 concen-
trations in POAG patients with myocilin mutations were
lower than in other POAG patients. The cited authors also
found that filtration surgery significantly reduced the
CD44 level in POAG patients [20]. Because our POAG
group was small and heterogeneous, the data are insuffi-
cient to permit subgroup analysis of our patient group.
Another explanation for the wide variation in sCD44 con-
centration seen in POAG AH might be that we were una-
ble to obtain POAG AH from patients who had not been
treated with glaucoma drugs. Nolan et al. showed that use
of carbonic anhydrase inhibitors tended to increase
sCD44 levels in AH. On the other hand, the use of pros-
taglandin inhibitors, which enhance AH outflow, tended
to decrease sCD44 concentration [20].
Myopic subjects are at a two- to three-fold increased risk
of glaucoma compared with nonmyopic subjects. The risk
was independent of other glaucoma risk factors and IOP
[21]. Recently, Li and colleagues found that the concentra-
tion of HA was lower in the vitreous of high-myopia
patients [22]. Highly myopic eyes show markedly reduced
amounts of the markers collagen and glycosaminogly-
cans, when compared with the sclera of emmetropic eyes
[23]. To the best of our knowledge, this is the first study
measuring sCD44 levels in degenerative myopic AH.
A significant limitation of the present study was the lack
of a patient group with both high-level myopia and glau-
coma. Further investigation is necessary to understand the
exact relationship between AH changes leading to glau-
coma in high-myopia patients.
The results of the present study reveal that the sCD44 level
in AH differed significantly between the POAG and con-
trol group. Although our sample size was small, statistical
significance was attained, and we thus suggest that sCD44
may serve as a protein marker of POAG. However, a study
with a larger number of patients is needed to confirm the
validity of this observation. sCD44 was slightly, but not
significantly, elevated in the AH of degenerative myopia
patients. Analysis of a larger patient series might reveal
that such patients do in fact have elevated sCD44, but per-
haps to an extent lower then seen in the AH of POAG
patients.
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